Stux Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Stux Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$1.2M	Sell	7,700 -1,600	-17%	-$253K	0.16%	177
2014 Q1	$1.42M	Sell	9,300 -500	-5%	-$79.5K	0.17%	160
2013 Q4	$1.3M	Buy	9,800 +200	+2%	+$24K	0.15%	170
2013 Q3	$1.11M	Sell	9,600 -1,000	-9%	-$110K	0.15%	186
2013 Q2	$978K	Buy	+10,600	New	+$1.02M	0.12%	198

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stux Capital Management's ALXN Position: Q2 2014 in Review

Stux Capital Management reduced its Alexion Pharmaceuticals (ALXN) stake by 17% in Q2 2014, selling an estimated $253K and leaving 7,700 shares worth $1.2M. The position accounts for 0.16% of the portfolio, ranked #177.

Stux Capital Management first reported a position in ALXN in Q2 2013 and has held it in 5 quarters since. The position peaked at $1.42M in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

Stux Capital Management held 7,700 shares of Alexion Pharmaceuticals worth $1.2M as of Q2 2014.
Stux Capital Management sold 1,600 Alexion Pharmaceuticals shares in Q2 2014, an estimated $253K.
Alexion Pharmaceuticals made up 0.16% of Stux Capital Management's portfolio in Q2 2014, its #177 holding.
Stux Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
Stux Capital Management's Alexion Pharmaceuticals position peaked at $1.42M in Q1 2014.
521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Stux Capital Management's 13F filing for Q2 2014, filed 14 Jul 2014.